Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences RNAi, miRNA and Epigenetics

Dmitry Samarsky's Biography

Dmitry Samarsky, SVP, Technology & Global Business , Olix Pharmaceuticals

Dmitry Samarsky, Ph.D., Vice President of Technology Development
Dr. Samarsky earned his Ph.D. in biochemistry and molecular biology from the University of Massachusetts (Amherst) in 1998, and from 1998 to 2001 he was the H. Arthur Smith Fellow for Cancer Research at the laboratory of Dr. Michael Green at the University of Massachusetts Medical School. From 2001 to 2007 Dr. Samarsky was developing and commercializing oligonucleotide-based technologies at Sequitur/Invitrogen and Dharmacon/ThermoFisher. In 2007 through 2011 he carried responsibilities for technology development at RXi, a biopharmaceutical company developing RNAi-based drugs. Dr. Samarsky has authored numerous research articles, reviews and book chapters. During the last 15 years he was invited to present at more than a hundred of academic and industrial scientific conferences.

Dmitry Samarsky Image

RNAi and Antisense Oligonucleotide in vivo Delivery for Therapeutic Applications

Wednesday, 14 November 2012 at 11:15

Add to Calendar ▼2012-11-14 11:15:002012-11-14 12:15:00Europe/LondonRNAi and Antisense Oligonucleotide in vivo Delivery for Therapeutic

Presentation will review the challenge of in vivo delivery of the RNAi and antisense therapeutic oligonucleotides, and will offer examples of successful solutions.

Add to Calendar ▼2012-11-13 00:00:002012-11-14 00:00:00Europe/LondonRNAi, miRNA and